Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Mercia Technologies plc. (1/25/18). "Press Release: Clinical Trials Software Secures £500k Investment from Mercia".

Organisations Organisation Mercia Fund Management Ltd. (Mercia Fund Managers)
  Group Mercia (Group)
  Organisation 2 Pharmaseal International Ltd.
Products Product clinical research software
  Product 2 venture capital
Index terms Index term Pharmaseal–SEVERAL: investment, 201801 1st financing round £500k from Mercia Fund Managers + angel investors
  Index term 2 ClinPhone–Parexel: investment, 2008 acquisition of ClinPhone by Parexel
Persons Person Cheema, Daljit (Pharmaseal 201602 CEO + Co-Founder before Parexel + ClinPhone)
  Person 2 Patel, Ashish (Ash) (Mercia Technologies 201801 Investment Manger at Mercia Fund Managers)

A Nottingham business which is developing new software to help pharmaceutical companies to manage clinical trials more effectively has secured a £500,000 equity investment from Mercia Fund Managers and angel investors.

PHARMASEAL International was established in 2016 by Daljit Cheema and Sara Rutner, who both have extensive experience in the pharmaceutical industry and previously held senior roles at pharma IT specialists ClinPhone Group and PAREXEL.

The two founders have already developed a prototype product. The funding will allow them to roll out their first module – a trial management platform that allows clinical trial operators to manage and monitor their clinical trials in accordance with good clinical practice (GCP) regulatory standards.

The deal also reunites the founders with their former boss Dr Neil Rotherham, the founder and ex-CEO of ClinPhone which was sold to PAREXEL in 2008. He has now joined PHARMASEAL as its Chairman.

PHARMASEAL’s cloud software is designed for the global pharmaceutical SME market, unlike the current software solutions on the market which are complex, costly and aimed at multinationals. The team also plan to release two further modules – a patient safety tool to identify any adverse outcomes during clinical trials, and a license and regulatory management tool allowing pharma companies to submit audit data to regulatory authorities. While Daljit is based at the company’s headquarters in Nottingham, co-founder Sara leads its office in New Jersey which is targeting the US market.

Daljit, PHARMASEAL’s Chief Executive Officer, said:

"This investment is important in allowing PHARMASEAL to complete product development and endorses the innovation in developing a unified control and governance platform for clinical trials"

Dr Ash Patel, Investment Manager with Mercia Fund Managers, said:

“There is a growing number of smaller pharmaceutical companies developing innovative products but they often have difficulty in gaining regulatory approval because of the weaknesses in their audit systems. Pharmaseal’s software will help them manage the process more effectively, from clinical trials to building a clear audit trail and submitting the right data to regulators. It will help SME firms to bring new drugs and devices to market more quickly and at lower cost.”

Record changed: 2020-01-04


Picture [iito] Made Without Love 650x80px

More documents for Mercia (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top